The international WAO/EAACI guideline for the management of hereditary angioedema - the 2017 revision and update.

Maurer M1, Magerl M1, Ansotegui I2, Aygören Pürsün E3, Betschel S4, Bork K5, Bowen T6, Balle Boysen H7, Farkas H8, Grumach A9, Hide M10, Katelaris C11, Lockey R12, Longhurst H13, Lumry W14, Martinez-Saguer I15, Moldovan D16, Nast A17, Pawankar R18, Potter P19, Riedl M20, Ritchie B21, Rosenwasser L22, Sánchez-Borges M23, Zhi Y24, Zuraw B25, Craig T26.

Author information

Abstract

Hereditary angioedema (HAE) is a rare disease and a serious health problem, globally and for affected patients and their families. The pathophysiological background is primarily a vascular reaction to an overshooting local production of bradykinin. Evidence-based recommendations are needed to inform and guide clinical decision makers. This is the first revision and update of the global guideline for the diagnosis and management of HAE[5]. It was developed by the World Allergy Organization (WAO) in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI). This article is protected by copyright. All rights reserved.

KEYWORDS:

GRADE ; C1-inhibitor; Hereditary angioedema; diagnosis; guideline; individualized therapy; management; prophylaxis; quality of life; recommendations; self-administration; therapy